Nevertheless, to date, intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative approach for AML and MDS patients with TP53 aberrations [39,40]. The gene discussed is TP53; the disease is acute myeloid leukemia.